144 related articles for article (PubMed ID: 18230556)
1. Changes in cellular immunity during chemotherapy for primary breast cancer with anthracycline regimens.
Wijayahadi N; Haron MR; Stanslas J; Yusuf Z
J Chemother; 2007 Dec; 19(6):716-23. PubMed ID: 18230556
[TBL] [Abstract][Full Text] [Related]
2. Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy.
Murta EF; de Andrade JM; Falcão RP; Bighetti S
Tumori; 2000; 86(5):403-7. PubMed ID: 11130570
[TBL] [Abstract][Full Text] [Related]
3. Acute hematologic feasibility of G-CSF supported dose-escalated FEC therapy as adjuvant treatment after breast cancer surgery.
Ottosson S; Magnusson K; Hultborn R
Anticancer Res; 1999; 19(5C):4429-34. PubMed ID: 10650787
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of two different regimens as neoadjuvant chemotherapy for breast cancer].
Yang D; Tong F; Cao Y; Liu P; Zhou B; Liu H; Qiao X; Zhang J
Zhonghua Zhong Liu Za Zhi; 2002 May; 24(3):303-5. PubMed ID: 12515634
[TBL] [Abstract][Full Text] [Related]
5. [Comparative study of chemosensitivity and efficacy between pirarubicin and epirubicin in breast cancer].
Zang MF; Zhang YM; Zhi YH; Zhai Z; Zhang M; Gu F; Zhi XC
Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1388-92. PubMed ID: 21756809
[TBL] [Abstract][Full Text] [Related]
6. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer.
Trudeau M; Charbonneau F; Gelmon K; Laing K; Latreille J; Mackey J; McLeod D; Pritchard K; Provencher L; Verma S
Lancet Oncol; 2005 Nov; 6(11):886-98. PubMed ID: 16257797
[TBL] [Abstract][Full Text] [Related]
7. Impact of anthracycline dose on quality of life and rehabilitation in breast cancer treatment.
Hokken JW; van der Cruijsen-Raaijmakers M; Schep G; Vreugdenhil G
Neth J Med; 2009 Jun; 67(6):220-5. PubMed ID: 19749391
[TBL] [Abstract][Full Text] [Related]
8. Reference ranges of lymphocyte subsets in healthy adults and adolescents with special mention of T cell maturation subsets in adults of South Florida.
Valiathan R; Deeb K; Diamante M; Ashman M; Sachdeva N; Asthana D
Immunobiology; 2014 Jul; 219(7):487-96. PubMed ID: 24661720
[TBL] [Abstract][Full Text] [Related]
9. Effect of different neoadjuvant chemotherapy regimens on locally advanced breast cancer.
Coskun U; Gunel N; Onuk E; Yilmaz E; Bayram O; Yamac D; Cihan A; Ucan B; Yildirim Y; Celenkoglu G; Ozkan S
Neoplasma; 2003; 50(3):210-6. PubMed ID: 12937855
[TBL] [Abstract][Full Text] [Related]
10. Optimizing adjuvant breast cancer chemotherapy: rationale for the MA.21 study.
Trudeau ME
Oncology (Williston Park); 2001 May; 15(5 Suppl 7):7-13. PubMed ID: 11396366
[TBL] [Abstract][Full Text] [Related]
11. [Changes of lymphocyte subsets before and after chemotherapy in colorectal carcinoma patients].
Zhang GQ; Zhao H; Wen XY; Li JY; Wu LL; Jiao SC
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Apr; 35(2):155-60. PubMed ID: 23643003
[TBL] [Abstract][Full Text] [Related]
12. The effect of anthracycline-based (epirubicin) adjuvant chemotherapy on plasma TAFI and PAI-1 levels in operable breast cancer.
Demirkan B; Ozcan MA; Glu AA; Yüksel F; Undar B; Alakavuklar M
Clin Appl Thromb Hemost; 2006 Jan; 12(1):9-14. PubMed ID: 16444429
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of host immunity and side effects in breast cancer patients treated with adjuvant chemotherapy (FEC therapy)].
Nagashima Y; Sanpei N; Yamamoto S; Yoshino S; Tangoku A; Oka M
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1550-2. PubMed ID: 16315865
[TBL] [Abstract][Full Text] [Related]
14. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
Steingrimsdottir H; Gruber A; Björkholm M; Svensson A; Hansson M
Haematologica; 2000 Aug; 85(8):832-8. PubMed ID: 10942930
[TBL] [Abstract][Full Text] [Related]
15. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
Roché H; Fumoleau P; Spielmann M; Canon JL; Delozier T; Serin D; Symann M; Kerbrat P; Soulié P; Eichler F; Viens P; Monnier A; Vindevoghel A; Campone M; Goudier MJ; Bonneterre J; Ferrero JM; Martin AL; Genève J; Asselain B
J Clin Oncol; 2006 Dec; 24(36):5664-71. PubMed ID: 17116941
[TBL] [Abstract][Full Text] [Related]
16. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
Del Mastro L; De Placido S; Bruzzi P; De Laurentiis M; Boni C; Cavazzini G; Durando A; Turletti A; Nisticò C; Valle E; Garrone O; Puglisi F; Montemurro F; Barni S; Ardizzoni A; Gamucci T; Colantuoni G; Giuliano M; Gravina A; Papaldo P; Bighin C; Bisagni G; Forestieri V; Cognetti F;
Lancet; 2015 May; 385(9980):1863-72. PubMed ID: 25740286
[TBL] [Abstract][Full Text] [Related]
17. [Equalization of spread of breast cancer chemotherapy regimen at general hospitals--with EC and FEC regimens].
Kitada N; Nakayama T; Morita S; Sasaoka H; Yamasaki H; Anami S; Tatsuta M; Furukawa H; Morimoto S; Miyabe T; Hasegawa K; Tabuse K; Takara K; Yokoyama T; Watari M
Gan To Kagaku Ryoho; 2008 Feb; 35(2):267-71. PubMed ID: 18281763
[TBL] [Abstract][Full Text] [Related]
18. Influence of physical activity on the immune system in breast cancer patients during chemotherapy.
Schmidt T; Jonat W; Wesch D; Oberg HH; Adam-Klages S; Keller L; Röcken C; Mundhenke C
J Cancer Res Clin Oncol; 2018 Mar; 144(3):579-586. PubMed ID: 29305709
[TBL] [Abstract][Full Text] [Related]
19. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG).
Polyzos A; Malamos N; Boukovinas I; Adamou A; Ziras N; Kalbakis K; Kakolyris S; Syrigos K; Papakotoulas P; Kouroussis C; Karvounis N; Vamvakas L; Christophyllakis C; Athanasiadis A; Varthalitis I; Georgoulias V; Mavroudis D
Breast Cancer Res Treat; 2010 Jan; 119(1):95-104. PubMed ID: 19636702
[TBL] [Abstract][Full Text] [Related]
20. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
Yagata H; Kajiura Y; Yamauchi H
Breast Cancer; 2011 Jul; 18(3):165-73. PubMed ID: 21290263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
